Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Şule Çalışkan Kamış has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Begül Yağcı

    Department of Pediatric Hematology and Oncology, Adana Faculty of Medicine, Adana City Training and Research Hospital, University of Health Sciences

    12 shared publications
  • Begül Yağcı-Küpeli

    Department of Pediatric Hematology and Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu.tr

    6 shared publications
  • Ayşe Selcan Koç

    Adana Faculty of Medicine, Department of Pediatric Radiology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey

    5 shared publications
  • Metin Çil

    Department of Pediatric Hematology and Oncology, Adana Faculty of Medicine, Adana City Training and Research Hospital, University of Health Sciences

    5 shared publications
  • Barbaros Şahin Karagün

    4 shared publications
  • Metin Çil

    Department of Pediatric Hematology and Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey, akdeniz.edu.tr

    4 shared publications

Latest Publications

  • Tedaviye Yanıtsız İmmün Trombositopeni: Bir Olgu Eşliğinde Tanı ve Yönetim

    by Şule Çalışkan Kamış, Barbaros Şahin Karagün

    İmmün trombositopeni (İTP), izole trombositopeni ile karakterize, trombosit yıkımının artışı ve trombosit üretiminin bozulması sonucu gelişen edinilmiş otoimmün bir hastalıktır. Çocukluk çağında çoğunlukla akut ve kendini sınırlayıcı seyir izlemekle birlikte, olguların yaklaşık %20–30’unda hastalık kronikleşmekte ve bu hasta grubunun bir kısmında standart tedavilere direnç gelişebilmektedir. Tedaviye dirençli İTP, kortikosteroidler, intravenöz immünoglobulin (IVIG) ve trombopoietin reseptör agonistleri gibi temel tedavi seçeneklerine rağmen yeterli trombosit yanıtı elde edilemeyen klinik durumları ifade eder ve yönetimi önemli klinik zorluklar içerir. Bu bölümde, çoklu tedavi basamaklarına rağmen yanıt alınamayan kronik İTP tanılı bir olgu sunulmuş ve güncel yaklaşımlar çerçevesinde değerlendirilmiştir. On yedi yaşında erkek hastada başlangıçta izole trombositopeni saptanmış, kemik iliği incelemesi periferik yıkım ile uyumlu bulunmuştur. İzlem sürecinde hastaya kortikosteroid ve IVIG tedavileri uygulanmış, ancak yalnızca geçici yanıt elde edilmiştir. Daha sonraki süreçte eltrombopag ve romiplostim tedavileri denenmiş, ancak trombosit değerleri 5.000–15.000/mm³ aralığında dalgalı seyretmiş ve kalıcı yanıt sağlanamamıştır. Hastada mukozal kanama ve spontan oküler ekimoz gelişmesi üzerine ileri basamak tedavi olarak rituksimab uygulanmış, ancak bu tedaviye de anlamlı yanıt alınamamıştır. Genetik incelemelerde patojenik varyant saptanmamıştır. Sunulan olgu, steroid, IVIG, trombopoietin reseptör agonistleri ve rituksimab tedavilerine yanıtsız seyreden nadir bir ultra-refrakter kronik İTP örneğini temsil etmektedir. Bu tür hastalarda altta yatan immün mekanizmaların heterojenliği nedeniyle bireyselleştirilmiş tedavi yaklaşımları, yeni tedavi seçenekleri ve multidisipliner değerlendirme büyük önem taşımaktadır.

  • Open Access

    Olgular Eşliğinde Erişkin Hematoloji

    by Orhan Ayyıldız, Eda Nuhoğlu, Melike Yeğin Kubatoğlu, Seda Yılmaz, Ferda Can, Mariye Doğru, Gülsüm Akgün Çağlıyan, Salih Cırık, Damla Çağla Patır, Eray Arslan, et al.

  • Congenital Ichthyosis and Jordans' Anomaly: A Diagnostic Clue to Chanarin‐Dorfman Syndrome

    by Harun Yildirim, Sule Caliskan Kamis, Onur Recep Gunduz, Savas Ozturk, Ebru Aydin Yildirim

  • Psychiatric morbidity and consultation trends in pediatric hematology–oncology inpatients

    by Şule Çalışkan Kamış, Burak Kamış, Cumali Yüksekkaya, Serkan Güneş, Metin Çil, Nihal Boz

    Purpose: This study aimed to evaluate psychiatric morbidity and consultation patterns among hospitalized pediatric hematology-oncology patients and to identify clinical factors associated with psychiatric diagnoses.Materials and Methods: This retrospective cross-sectional chart review was conducted at the pediatric hematology-oncology inpatient service of Adana City Training and Research Hospital. Medical records of patients aged 0–18 years who were hospitalized in the pediatric hematology-oncology service and received a child and adolescent psychiatry consultation between September 2022 and September 2025 were reviewed. Psychiatric diagnoses were established according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Results: A total of 126 unique pediatric hematology-oncology inpatients were included (mean age: 10.9 ± 4.6 years; 58.7% male). A psychiatric diagnosis was established in 76 patients (60.3%). The most common diagnoses were adjustment disorder in 26 patients (20.6%), major depressive disorder in 21 (16.7%), and anxiety disorders in 16 (12.7%). In multivariable analysis, female sex (OR: 3.23, 95% CI: 1.36–7.68), metastatic disease (OR: 2.63, 95% CI: 1.07–6.49), and low treatment adherence (OR: 6.42, 95% CI: 1.96–21.03) were independently associated with psychiatric diagnosis.Conclusion: Psychiatric morbidity is highly prevalent among hospitalized pediatric hematology-oncology patients requiring psychiatric consultation. Female sex, metastatic disease, and poor adherence to oncological treatment were identified as independent risk factors for psychiatric diagnosis.

  • Open Access

    Anxiety, depression, and quality of life in children with solid tumors: a single-center exploratory study of sociodemographic, clinical, school, and social functioning correlates

    by Şule Çalışkan Kamış, Burak Kamış, Metin Çil, Nihal Boz, Begül Yağcı

    Background: Children with solid tumors experience prolonged treatment, repeated hospital visits, and psychosocial stressors. This exploratory single-center cross-sectional study evaluated anxiety symptoms, depressive symptoms, and health-related quality of life in children with solid tumors and examined their associations with selected sociodemographic, clinical, school functioning, and social functioning variables. Methods: Fifty children aged 8–18 years with solid tumors were evaluated at a tertiary pediatric hematology-oncology center in Türkiye between August 2024 and August 2025. Validated Turkish versions of the Children's Depression Inventory (CDI), Screen for Child Anxiety Related Emotional Disorders (SCARED), Revised Child Anxiety and Depression Scale–Child Version (RCADS-CV), and Pediatric Quality of Life Inventory (PedsQL) were administered by a child and adolescent psychiatry specialist. The primary outcome was the SCARED total score. Sociodemographic and clinical variables were recorded. Results: The median age was 13 years. Clinically significant depressive symptoms (CDI ≥ 19) were detected in 16% of patients, and high anxiety risk (SCARED ≥25) in 56%. Median RCADS-CV total anxiety and depression scores were 42.0 and 44.5, respectively. Girls had higher PedsQL emotional functioning scores than boys ( p < 0.001), whereas school functioning did not differ significantly between age groups ( p = 0.124). In exploratory analyses, lower maternal education was associated with a higher likelihood of clinically significant depressive symptoms (Spearman's rho = −0.383, p = 0.006). Conclusion: Children with solid tumors showed a substantial burden of anxiety risk and depressive symptoms. Standardized psychosocial assessment may help identify children requiring emotional support and guide individualized, family-centered interventions. Larger longitudinal multicenter studies are needed to validate these exploratory findings.

  • Open Access

    Pediatric mediastinal tumor unveiled as T-cell prolymphocytic leukemia: diagnostic pitfalls—a case report

    by Şule Çalışkan Kamış, Barbaros Şahin Karagün, Fulya Adamhasan, Ayşe Selcan Koç

    T-cell prolymphocytic leukemia (T-PLL) is a rare and highly aggressive mature T-cell malignancy that predominantly affects older adults. Its occurrence in childhood is exceptionally uncommon and may mimic other neoplasms, such as lymphoma or thymoma, particularly when associated with mediastinal masses or generalized lymphadenopathy. A 13-year-old Turkish girl presented with severe respiratory distress. Thoracic imaging demonstrated a large anterior mediastinal mass. In the prevascular mediastinal compartment, the most common tumors include thymoma, germ cell neoplasms, and lymphoma. The initial needle biopsy was of limited diagnostic value due to crush artifacts and demonstrated a T-cell-predominant infiltrate with focal keratin positivity, initially suggestive of a thymic neoplasm. Based on this preliminary interpretation, empiric chemotherapy for presumed advanced thymoma was initiated. However, detailed systemic radiological assessment revealed that the mass was not confined to the mediastinum but also accompanied by widespread lymphadenopathy. Subsequent systemic radiological evaluation revealed widespread lymphadenopathy beyond the mediastinum, prompting an incisional lymph node biopsy. Immunohistochemical analysis revealed a neoplasm lacking an epithelial component (negative for P63, pancytokeratin, and cytokeratin) and composed entirely of lymphoid cells. The tumor cells showed diffuse positivity for CD45, CD3, CD5, CD8, and BCL-2, with a high Ki-67 proliferation index, and were negative for immaturity markers (CD34, TdT, CD33). Taken together, these findings supported a mature T-cell neoplasm most consistent with T-PLL, although the absence of molecular confirmation limited definitive diagnostic certainty. Bone marrow evaluation was non-diagnostic. This case illustrates the diagnostic challenges of pediatric T-PLL and demonstrates that a multidisciplinary correlation of clinical, histological, immunophenotypic, and molecular features-together with repeated biopsy and comprehensive immunophenotyping-can be decisive for timely and accurate diagnosis.

  • Open Access

    Computed tomography-derived sarcopenia, enteral nutritional support, and febrile neutropenia burden in children with acute lymphoblastic leukemia: a retrospective cohort study

    by Şule Çalışkan Kamış, Burak Kamış, Metin Çil, Nihal Boz, Ayşe Selcan Koç, Begül Yağcı

    Objective: This study aimed to evaluate computed tomography-derived sarcopenia and enteral nutritional support in relation to febrile neutropenia burden, hospital stay, and mortality in children receiving treatment for acute lymphoblastic leukemia. Materials and methods: This retrospective single-center cohort included 100 children aged 3–17 years with acute lymphoblastic leukemia treated between April 2020 and March 2024. Clinical data on febrile neutropenia episodes, neutropenia duration, severe neutropenia, hospital stay, enteral nutritional support, and febrile neutropenia-related mortality were collected from hospital records. Sarcopenia analysis was restricted to 50 patients with clinically indicated computed tomography images suitable for total psoas muscle area measurement. Total psoas muscle area was measured at the L4–L5 level. Sarcopenia was defined as a total psoas muscle area z-score < −2 according to age- and sex-specific reference values. Results: The median number of febrile neutropenia episodes was 6.5, ranging from 1 to 19. Febrile neutropenia-related mortality was observed in 17 patients. Forty-five patients received enteral nutritional support. Enteral nutritional support was associated with higher febrile neutropenia burden in unadjusted analysis; however, this was not interpreted as causal because enteral feeding may reflect underlying clinical severity. Among the 50 patients with total psoas muscle area data, 40 patients, corresponding to 80% of the imaged subgroup, were sarcopenic. Sarcopenia was not significantly associated with febrile neutropenia frequency, severe neutropenia, mortality, or hospital stay. In exploratory adjusted analysis, enteral nutritional support showed a borderline but non-significant association with febrile neutropenia frequency (IRR: 1.16, 95% CI: 1.00–1.36, p = 0.052). Conclusion: Computed tomography-derived sarcopenia was common among imaged children with acute lymphoblastic leukemia but was not independently associated with febrile neutropenia burden or hospital stay. Enteral nutritional support should be interpreted as a marker of clinical vulnerability rather than a causal determinant of febrile neutropenia.

  • Open Access

    Maxillary mesenchymal chondrosarcoma harboring HEY1::NCOA2 fusion in a 13-year-old girl: a rare case report and literature review

    by Şule Çalışkan Kamış, Begül Yağcı, Ayşe Selcan Koç, Güliz Durak, Ali Yitik

    Background: Mesenchymal chondrosarcoma (MCS) is a rare and highly aggressive subtype of chondrosarcoma, accounting for less than 1% of all chondrosarcomas. It predominantly affects adolescents and young adults and frequently arises in craniofacial bones and soft tissues. Diagnosis is challenging because of significant histological overlap with other high-grade spindle cell sarcomas, particularly when the cartilaginous component is minimal or absent. The identification of the HEY1::NCOA2 gene fusion has emerged as a highly specific molecular marker for MCS, substantially improving diagnostic accuracy and providing potential therapeutic implications. Case presentation: We report the case of a 13-year-old girl who presented with a 3-month history of progressive right cheek swelling. Imaging revealed a destructive mass in the right maxillary sinus. Histopathological evaluation demonstrated a high-grade spindle cell tumor, initially interpreted as fibrosarcoma, showing diffuse vimentin positivity, a high Ki-67 proliferation index (35%–40%), and CD34 negativity. Comprehensive molecular analysis confirmed a pathogenic HEY1::NCOA2 gene fusion, while ETV6::NTRK3 fusion was excluded. The patient was treated with VAC chemotherapy (vincristine, actinomycin D, cyclophosphamide), local radiotherapy (60 Gy), cranial prophylactic radiotherapy (12 Gy), and subsequent debulking surgery. Follow-up 18 F-FDG PET/CT demonstrated a partial metabolic response. Given persistent disease and molecular evidence suggesting activation of the PI3K/AKT/mTOR pathway in MCS, maintenance therapy with the mTOR inhibitor sirolimus was initiated. Conclusion: This case highlights the pivotal role of molecular diagnostics—particularly RNA sequencing—in establishing the diagnosis of mesenchymal chondrosarcoma and differentiating it from other high-grade pediatric sarcomas with overlapping morphology. Identification of the HEY1::NCOA2 fusion not only confirms the diagnosis but may also support biologically targeted therapeutic strategies. Multimodal treatment incorporating chemotherapy, radiotherapy, surgery, and targeted maintenance therapy can achieve meaningful disease control in aggressive craniofacial MCS. To our knowledge, this represents one of the very few reported pediatric cases of maxillary MCS with confirmed HEY1::NCOA2 fusion managed with sirolimus-based maintenance therapy.

  • Open Access

    Evaluation of iron accumulation during childhood cancer treatment

    by Şule Çalışkan Kamış, Metin Çil, Begül Yağcı, Barbaros Şahin Karagün

    Background: Iron overload is a major concern in pediatric oncology, especially among patients receiving frequent blood transfusions. Although serum ferritin (SF) is widely used as a surrogate marker, T2* magnetic resonance imaging (MRI) of the liver and heart remains the gold standard for quantifying tissue iron deposition. This study evaluated the relationship between serum ferritin levels and T2* MRI findings in pediatric cancer patients, focusing on those with ferritin levels >1,000 µg/L. Methods: This retrospective study included patients aged 10–25 years diagnosed with malignancies and followed at the Pediatric Hematology and Oncology Clinic of Adana City Training and Research Hospital between June 2023 and December 2024. The upper age limit was chosen to include adolescent and young adult patients treated under pediatric oncology protocols. Serum ferritin and C-reactive protein (CRP) levels were measured during afebrile, infection-free periods. Elevated ferritin levels concurrent with high CRP were re-evaluated to exclude inflammation-related effects. Transfusion frequency and ferritin levels were recorded at 3, 6, and 12 months. Patients with ferritin >1,000 µg/L underwent cardiac and hepatic T2* MRI to assess organ-level iron burden and determine the need for chelation therapy. Results: Twenty-eight patients (median age: 14 years; 12 females, 16 males) were analyzed. The median baseline ferritin level was 32.5 µg/L. A significant correlation was found between transfusion number and ferritin >1,000 µg/L within the first 3 months ( p = 0.029, r = 0.48) and for total annual transfusions ( p = 0.001). Correlations at 3–6 months ( p = 0.061, r = 0.42) and 6–12 months ( p = 0.065, r = 0.39) were not statistically significant. Three patients (10.7%) had ferritin >1,000 µg/L—two with acute lymphoblastic leukemia and one with non-Hodgkin lymphoma. Among them, one underwent bone marrow transplantation, one died, and one had moderate hepatic but normal cardiac iron on T2* MRI. Conclusion: Iron overload is a preventable but clinically important complication in pediatric oncology. Combined monitoring with serum ferritin and T2* MRI enables early detection and timely management. Larger multicenter studies are needed to optimize screening intervals and chelation strategies in this high-risk group.


  • Open Access

    SUVmax on 18 F‐FDG PET/CT and Histopathological Necrosis in Osteosarcoma and Ewing Sarcoma

    by Şule Çalışkan Kamış, Metin Çil, Emel Koçyiğit Deveci, Zeynel Abidin Taş, Begül Yağcı

    Purpose: This study is aimed at evaluating the relationship between preoperative 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F‐FDG PET/CT) findings and histopathological necrosis rates following chemotherapy in patients diagnosed with osteosarcoma (OST) and Ewing sarcoma (EWS). Methods: Patients diagnosed with OST and EWS between 2017 and 2023 were retrospectively analyzed. Data recorded included preoperative 18 F‐FDG PET/CT findings, demographic characteristics, histopathological diagnosis, maximum standardized uptake value at diagnosis (SUVmax1), maximum standardized uptake value after neoadjuvant chemotherapy (SUVmax2), the SUVmax change ratio (SUVmax2/SUVmax1 = SCR), and the percentage of tumor necrosis in resected specimens. Results: A total of 49 patients (33 OST and 16 EWS) were included, consisting of 22 females (44.9%) and 27 males (55.1%) with a median age of 12 years (range: 4–20). Median SUVmax1, SUVmax2, and SCR values were 6.8 (0–22.5), 2.5 (0–9.42), and 0.38 (0–1.44), respectively. The median tumor necrosis percentage was 20% (range: 0–100). Stratification according to SUVmax2 (< 2.5 vs. ≥ 2.5) revealed no significant difference in necrosis percentage ( p = 0.234). No significant correlation was observed between SCR and necrosis percentage ( p = 0.102). However, a significant inverse correlation was found between SUVmax2 and necrosis percentage in the overall cohort ( p = 0.040, r = –0.295), which was more pronounced in OST patients ( p = 0.014, r = –0.426). Conclusion: 18 F‐FDG PET/CT is a valuable imaging modality for predicting histopathological response in solid tumors. Consistent with adult studies, our findings demonstrate that post‐NACT FDG uptake is inversely correlated with tumor necrosis percentage, particularly in pediatric OST patients. These results highlight the potential of 18 F‐FDG PET/CT as a noninvasive prognostic tool to assist in early identification of poor responders.